The melanoma pipeline, which is typically underserved due to stubborn R&D challenges, is being praised for its levels of innovation as of late with 579 programs active across all stages of development, with 226 first-in-class programs in the pipeline, acting on 138 distinct first-in-class molecular targets. This accounts for 38% of all programs with a disclosed molecular target and reflects the high degree of innovation in this indication, according to business intelligence provider GBI Research.
At the start of 2016, the industry predicted many market access trends. As we come to the end of the year, let us look at the market access trends predicted at the start of 2016. How have these predictions unfolded so far and what will be the next set of trends for the coming year?
With several patent expiries in 2015 and 2016, there was high expectation that a significant portion of the biologics market would shift to biosimilar use by 2016, especially in the areas of diabetes, rheumatology, and in tendering markets. I
2017 is set to be an exciting time for pharma companies to develop and adopt new strategies and models to stay ahead of both the expected and unexpected market trends.
Health experts and medical personnel will be the first to say that the medical field is lagging behind when it comes to technology and innovation.
The last quarter of 2016 was certainly not short of activity with a £84 million pharma fine issued in regards to drug pricings, an investigation into a suspected supply chain breach and numerous therapeutic approvals.
Looking ahead, the United States is expected to retain its dominant position within the toxicology testing market, although as with many areas of the pharmaceutical industry, the greatest levels of growth are expected to be seen in Asia Pacific.
The collection of late phase clinical oncology trial data has seen an increasing emphasis placed on the collection of economic figures following a compound being brought to market. As the competition for new compounds and devices continue to escalate in parallel to the costs of running effective trials, particularly in the high-cost oncology trial market, a contract research organisation that has the scale and expertise to map out economic considerations, early and inexpensively, provides an attractive value add for the discerning late-phase trial sponsor.
As China continues to transition from the center of global manufacturing to a more innovation based economy, Israel’s technology sector has attracted increasing Chinese attention. While this is generally the case, it is particularly applicable to Chinese interest in Israel’s life sciences and medtech industry which has experienced rapid growth and development in recent years. Indeed, this industry is playing a pivotal role in the world healthcare market, underpinned by its innovation and excellence in academic research, government support and increasing funding options. These factors are leading to ever more success and record investments, especially from China.
The meeting was kicked off by John Wise, Executive Director at Pistoia Alliance, who shared a delightful, anecdote-filled review of the current pharma R&D business landscape. In his talk, he gave detailed evidence of how different pharma companies were comparing the amount they spend to bring each new drug to market. He highlighted just ‘being big’ was not enough, and explained how a company’s approach to innovation also plays a role in the drug discovery process.